Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1038/s41591-023-02465-7
文献链接: https://www.nature.com/articles/s41591-023-02465-7
其他信息:
出版社: Springer Science and Business Media LLC
作者: Manish A. Shah; Kohei Shitara; Jaffer A. Ajani; Yung-Jue Bang; Peter Enzinger; David Ilson; Florian Lordick; Eric Van Cutsem; Javier Gallego Plazas; Jing Huang; Lin Shen; Sang Cheul Oh; Patrapim Sunpaweravong; Hwoei Fen Soo Hoo; Haci Mehmet Turk; Mok Oh; Jung Wook Park; Diarmuid Moran; Pranob Bhattacharya; Ahsan Arozullah; Rui-Hua Xu
全文下载地址: https://www.nature.com/articles/s41591-023-02465-7.pdf
